Bottneuro AG

Proud to announce the most promising Swiss MedTech Startups and Scale-Ups of 2024, picked by a panel of 100 leading investors and industry experts. Read the full article: https://lnkd.in/dU99-nRf Discover the 15 Medtech Startups that impressed the TOP 100 Swiss Startup Award Jury in 2024: Adiposs - Imaging Body Fat to Save Lives. https://lnkd.in/dxBd93GE Avelo - Breath collector for better diagnosis of pneumonia. https://lnkd.in/dp3u5xEn Artiria Medical - Fighting strokes, saving lives. https://lnkd.in/dQDyrSPk Bottneuro AG - 3D-printed wearable for brain recording and stimulation! https://lnkd.in/dfziw6_D CustomSurg - Rethinking Treatment of Complex Trauma Surgery. https://lnkd.in/d-BMsMJQ EarlySight SA - Imaging early signs of retinal diseases years in advance. https://lnkd.in/eQGSQeUv ENANTIOS - Simple solutions for complex molecules. https://lnkd.in/dW9JK8tJ FluoSphera - Predictive drug profiling with multi-organoid systems. https://lnkd.in/djGNZmPm Herosupport SA - Personalized breast immobilization (shells) for radiotherapy. https://lnkd.in/dHwgdSfY Nanoflex Robotics - Endo and Neuro vascular remote control soft robotic system. https://lnkd.in/dDVXY59z Neurosoft Bioelectronics - Soft implantable electrodes for the nervous system. https://lnkd.in/dDaYpx_h Terapet SA - Next Generation Imaging Technology for nuclear medicine. https://lnkd.in/dhGcDfQH TWIICE - Powered exoskeletons for walking assistance. https://lnkd.in/dA6hEk3c About: The annual ranking of the TOP 100 Swiss Startups has become a benchmark in Switzerland’s startup ecosystem - and beyond. Every year, a panel of 100 leading investors and startup experts chooses the 100 most innovative and promising Swiss startups. Each jury member nominates 10 Swiss startups that are fewer than five years old and show the greatest commercial potential. They assign 10 points for the first place and one point for the tenth place. The companies with the most points make it into the TOP 100 Swiss Startup Ranking. #SwissStartups #MedTech #TOP100SSU

Great feeling to be back at the Novartis campus in Basel! The campus now offers a lot of support and opportunities to Startups! Today: Innosuisse coaching session with the superb team of Bottneuro AG : Bekim Osmani, PhD and Alois C. Hopf, PhD ! An impressive development! Here is how it works: MRI scan of a patient (eg with Alzheimer’s disease) - optimization of brain stimulation based on individual anatomy - 3d printing of an individual cap - to be used for 1 hour of stimulation per day in clinic or home setting. Measurable clinical improvement already after the first sessions! Traction: RA (CE class IIa) and IP (3 patents) in place. Clinical going on. First patients treated with success! Further use cases (eg migraine) developed. Great pleasure to work with this team!

Die fünfte Ausgabe der Longevity Investors Conference – ein voller Erfolg Die Longevity Investors Conference (LIC) hat sich erneut als führende Veranstaltung für den schnell wachsenden Sektor der Langlebigkeitsinvestitionen erwiesen. Die fünfte Ausgabe fand vom 24. bis 27. September im renommierten Le Grand Bellevue Hotel in den malerischen Schweizer Alpen von Gstaad statt. Die diesjährige Ausgabe brachte führende Persönlichkeiten aus dem Bereich Langlebigkeit mit prominenten privaten und institutionellen Investoren zusammen und bot eine einzigartige Plattform für Wissensaustausch, Networking und Zusammenarbeit. #Longevity #Langlebigkeit Longevity Investors Lucia Kupcova Marc P. Bernegger Dr. Tobias Reichmuth Hilary Brueck Bjorn Rosendahl David A. Sinclair A.O., Ph.D. Nir Barzilai David Furman Aubrey de Grey Bryan Johnson Brian Kennedy Kayla Barnes-Lentz Evelyne Bischof, MD, PhD Ronit Raphael Paolo Giacomoni Alexander S. Dr. Emil Kendziorra Dr Matt Pywell Elisabeth Roider, MD, PhD, MBA Andrea B. Maier Laura Deming Alex Colville Julie Pelcener Smithwhite Yuta Lee Bruno Balen Ella Davar Dr. Kati Ernst Duri Granziol Chris Monkman Sabinije von Gaffke Phil Newman Alexa Mikhail Martina Fuchs MICREGEN LTD MoglingBio Inc Kyttaro Therapeutics Leucadia Therapeutics metaShape Pharma Propion AKA How to Slow Time, Inc™ Bottneuro AG https://lnkd.in/e-dJTVNv

🧠 On this World's #Alzheimer's Day, we are excited to announce that we've just started #treating our 5th #patient in #Switzerland, with more in the pipeline. 🧠 At #Bottneuro, we stand firm in our commitment to exploring the potential of our non-invasive #neurostimulation technology to address #Alzheimer's disease. We believe we have gained valuable insights into the #mechanism of gamma stimulation in Alzheimer's. Our therapy specifically targets #inhibitory #interneurons, whose reduced activity in Alzheimer’s leads to the overexcitation of excitatory neurons, resulting in calcium overload and #neuronal #death. Our #personalized 40 Hz #stimulation aims to restore the activity of these interneurons in the brain's affected regions, potentially preventing further cognitive decline. As we treat more #patients, we move closer to unlocking the full potential of this promising approach in the fight against Alzheimer's. #AlzheimersDay #Neurostimulation #GammaTherapy #Bottneuro #AlzheimersResearch #BrainHealth #Longevity https://lnkd.in/dPa5Qvj5

🎉 A medication-free and personalized approach for Alzheimer's treatment? Join us in celebrating innovation for a better world! Our resident Bottneuro AG at Switzerland Innovation Park Basel Area - Novartis Campus was selected among the Top 100 Swiss Startup Award 2024, powered by Venturelab! We are incredibly proud to celebrate Bottneuro's remarkable achievement. This recognition highlights the path they are carving out in the field of neuroscience. Well done, Bekim Osmani, PhD & team! 👏 Bottneuro is pioneering innovative solutions for the treatment of Alzheimer's disease through personalized neuromodulation therapies. Their innovation improves the diagnosis and treatment of neurological diseases. Curious about the dynamic environment that acts as the source of these success stories? 👉 Learn more about our unique co-working space on the Novartis Campus: https://lnkd.in/ey--7_D3 Alois C. Hopf, PhD | Mahyar Joodaki | Annina Ruffner | Marc Funken | Mathias Recalde Koller | Griffin Rodgers Rahel Schneider #innovation #startups #healthcare #neuroscience #TOP100SSU

We’re incredibly proud to announce that Bottneuro has been chosen as one of the TOP 100 Swiss Startups this year! 🚀✨ This achievement highlights our dedication to revolutionizing the treatment of neurological disorders through innovative technology. A big THANK YOU to Venturelab for making this happen and congratulations to all the amazing startups who are shaping the future with their groundbreaking ideas.     #TOP100SSU #Startup #Swissmade #Innovation #Healthcare #Alzheimer 

Revolutionizing Alzheimer's Treatment with Personalized Neurostimulation 🌟 Bottneuro AG, a Basel-based startup, partnered with IMT to develop a groundbreaking non-invasive therapeutic device for Alzheimer's patients. This neurostimulator, featuring 32 electrode channels, offers personalized transcranial electrical stimulation (tES) to target specific brain regions. With a compact design, integrated EEG capabilities, and a user-friendly tablet interface, this device empowers home-therapy, reducing the need for constant professional supervision. IMT's agile development approach, from rapid prototyping to regulatory compliance, accelerated the device's time to market. Now registered with Swissmedic and MHRA, this innovation is ready to make a difference. Read more about the project here: https://lnkd.in/dBgWvvKi Learn how IMT can help bring your medical device ideas to life: https://lnkd.in/d3nxS_gx #medtech #alzheimers #startup #makingideaswork

🚀 Exciting developments in Alzheimer's research! A recent review highlights the crucial role of fast-spiking parvalbumin (PV) #interneurons in controlling #brain networks and memory processing. These PV interneurons, known for their ability to fire at high frequencies, are vital for maintaining healthy neural circuits. Dysfunctional PV neurons are linked to various disorders characterized by network disruptions and cognitive decline, including #Alzheimer’s disease (AD). This review highlights PV interneuron impairment as a key driver of AD and related memory issues. This finding aligns with our work at Bottneuro AG, where we are pioneering #personalized #neurostimulation technology designed to restore PV interneuron function in #Alzheimer's patients. We invite clinicians in #Switzerland to join our Priority Access Program and be part of this groundbreaking journey in #Alzheimer's care. Together, we can make a difference. #Alzheimer #Neuroscience #Neurostimulation #Innovation #HealthcareTech #NeuroClinics #PriorityAccessProgram Here is the full article: https://lnkd.in/gzv4BR4r

🌟 Revolutionizing Alzheimer's Therapy with Bottneuro AG and HP Multi Jet Fusion Technology 🌟 🔬 Bottneuro: Pioneering Personalized Neuromodulation Therapy for Alzheimer’s Disease 🔬 🚀 Bottneuro AG, a spin-off from the University of Basel, is transforming Alzheimer's treatment with their Miamind® Neurostimulator. This groundbreaking, non-invasive therapy improves cognitive function and quality of life by delivering precise electrical stimulation through a personalized cap created using HP Multi Jet Fusion 3D Printing Technology. 🔔 Recent Highlights: • Completion of First Clinical Trial: Demonstrated safety and feasibility, with no serious adverse effects. • Personalized Home-Based Therapy: Utilizing advanced 3D-printed headsets tailored from MRI scans. • Innovative Design Collaboration: Partnering with ETH Zürich for a fully digitalized process in headset design and manufacturing. • Global Expansion: Now available in Switzerland, UK, and EU, with plans to expand to MENA, Japan, Australia, and pursue FDA approval. Bottneuro’s mission is to make Alzheimer’s as manageable as diabetes, restoring independence and cognitive function to millions. 👉 Watch the Video below to Learn More About the Benefits and Innovation Behind This Technology #HP3DPrinting #AlzheimersTherapy #InnovationInHealthcare #3DPrinting #Neurostimulation #HealthcareRevolution #MedicalInnovation #Bottneuro #DigitalHealth #HPJetFusion

While we have just learned about the direction that Ursula von der Leyen envisions for Europe over the next five years—aimed at fostering innovation and technologies as part of a broader life sciences strategy—it is wonderful to see that patients in #Switzerland already have access to innovative solutions like Miamind®.   Neurostimulation is known to be beneficial for cognitive dysfunction and several other brain conditions. Bottneuro AG is working tirelessly not only to democratize this solution and bring it to patients globally but also to personalize it according to the specific brain characteristics of each patient. By using MRI imaging, they are able to deliver targeted brain stimulation.    If you are a neurologist, or an investor and want to learn more about the potential of the Priority Access Program for Miamind®, please reach out. #brainhealth, #neurosceince, #alzheimer